Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2017-07-26 | 2017-10-05 | 17257 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2017-08-23 | 2017-10-03 | 20113 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2017-10-23 | 2017-12-20 | 26625 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2017-11-07 | 2018-01-11 | 28564 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2017-11-09 | 2018-01-10 | 28689 |
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2017-12-14 | 2018-04-05 | 32818 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2018-01-22 | 2018-05-23 | 36940 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2018-02-01 | 2018-05-25 | 37997 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2018-02-21 | 2018-05-01 | 40362 |
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2018-02-21 | 2018-05-23 | 40367 |
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2018-07-16 | 2018-10-12 | 55842 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2019-02-06 | 2019-03-29 | 74914 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2019-02-06 | 2019-03-29 | 74917 |
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2019-02-06 | 2019-03-29 | 74922 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2019-02-13 | 2019-03-30 | 75623 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2019-02-24 | 2019-03-29 | 76729 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2019-05-15 | 2019-06-24 | 84128 |
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2020-02-13 | 2020-06-02 | 106006 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2020-04-13 | 2020-06-02 | 111925 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2020-06-04 | 2020-07-28 | 116547 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |